Clinical Research Directory

Inclusion Criteria: 1. Willing and able to provide written informed consent. 2. Male or female, aged 18-70 years old inclusive at study entry. 3. ECOG (Eastern Cooperative Oncology Group) 0 or 1. 4. Histologically-proven primary colorectal tumor. 5. Bilateral, limited at liver and non-resectable CRLM by consensus in Multidisciplinary Committee. 6. Resection of primary colorectal tumor according oncological principles and adequate TNM stage. 7. Time from primary colorectal tumor resection to transplant ≥ 12 months. 8. Primary colorectal tumor stage ≤ T3N1. If time between primary tumor resection is ≥ 2 years, stage T4N0 or T4N2 is accepted. 9. No signs of extrahepatic metastatic disease according to PET/CT scan, CT and pelvic MRI. 10. The patient has undergone systemic chemotherapy for a minimum of 3 months at the time of screening and maximum of 2 lines of fluoropyrimidine based chemotherapy combined or not with irinotecan or oxaliplatin associated or no not with targeted therapy based in molecular biomarkers. 11. Demonstrated stability or partial regression of CRLM following RECIST criteria v 1.1., at minimum 3 months since the last treatment received and immediately prior to screening. 12. CEA (Carcinoembryonic antigen) values ≤ 80 µg/L immediately prior to screening. 13. Adequate blood test regarding: * Creatinine ≤1.25 x upper normal level or estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73m2 using following the Chronic Kidney disease epidemiology collaboration (CKD-EPI) formula. * Platelets ≥80 × 109/L * Neutrophiles ≥ 2.5 × 109/L 14. Patients with hepatic failure after resection will be considered if it occurs as a consequence of an inadequate preoperative estimation of the functional volume that would have contraindicated the surgery. They should meet the inclusion criteria and none of the exclusion criteria. Exclusion Criteria: 1. Largest Lesion \>5.5cm immediately prior to screening 2. Patients with Lynch Syndrome 3. BRAF mutation and/or primary tumor of microsatellite instability (MSI) 4. Recurrence of primary tumor confirmed by colonoscopy or pelvic MRI within the last 12 months prior to screening. 5. Previous or concurrent cancer in the last 5 years. Any cancer curatively treated 5 years prior to entry or treated basal cell carcinoma is permitted. 6. Substance abuse, medical, psychological or social conditions that may interfere with the patient´s participation in the study or evaluation of the study results. 7. Cardiac or pulmonary disease uncontrolled as contraindication for any surgical procedure. 8. Active infection. 9. Pregnant or breast-feeding patients 10. Any reason why in the opinion of the investigator, the patient should not participate.